PhagoMed Biopharma GmbH is a pre-clinical biotech company focused on accelerating the re-introduction of phage therapy into Western medical practice. PhagoMed builds on the treatment expertise of its co-founders Prof. Dr. Wippermann and PD Dr. Trampuz, who have jointly treated ~20 patients with bacteriophages as a last resort over the past 15 years. As of early 2018, PhagoMed has completed its seed financing round (private investment
ViruSure is a privately owned biotech company specialising in the virus and prion safety testing of biopharmaceutical products. We offer contract testing services and a wealth and breadth of expertise to ensure you meet all relevant pathogen safety testing requirements. Our goal is to ensure that the strategy we develop with you will provide a high chance of success in satisfying all regulatory requirements at the first attempt.
Celeris Therapeutics ist ein Deep Learning Unternehmen, das mittels innovativer, computerbasierter Methoden genau diese Targets abbaubar macht und somit das Potenzial hat, Arzneimittel für Alzheimer und ähnliche Krankheiten zu entwickeln. Die technische Lösung von Celeris Therapeutics ist die Web-Applikation Celeris One. Potenzielle Nutzer dieser Applikation sind Pharma- und Biotech-Unternehmen mit Fokus auf Targeted Protein Degradation. Sie besteht aus 3 Modulen: Xanthos, Hephaistos und Hades.
Sola Diagnostics bestimmt die Risiken, an verschiedenen gynäkologischen Krebsarten zu erkranken und kontrolliert den Erfolg entsprechender präventiver Maßnahmen - bevor - der Krebs ausbricht! - Weil Krebsprävention deutlich besser ist - als Krebstherapie.
Akribes Biomedical is dedicated to the improvement of chronic wound therapy. We developed the first theranostic assay platform to enable personalized pharmacological therapy of chronic wounds. Based on this platform we identified and patented drugs with so far unknown potential for chronic wound healing, which will be developed as novel wound therapeutics.
Our mission is to make a novel therapeutic approach a reality in Peritoneal Dialysis (PD) – an area where clinicians and patients saw disappointingly little innovation in decades. Zytoprotec, a biomedical company founded in 2007, has consistently moved its lead product – PDprotec® – from basic research through preclinical and clinical development. The product is currently prepared to enter a pivotal Phase III clinical trial.
APEPTICO Forschung und Entwicklung GmbH is a privately-held development stage biotechnology company in Vienna, Austria, developing peptide-based products targeting life-threatening pulmonary diseases.
Pivaris BioScience GmbH is a privately held Research
THT Biomaterials GmbH aims to overcome major methodological issues at the bottom of today’s drug development, tissue engineering and regenerative medicine research practices leading to false positive or negative results. A new visionary platform technology is under development that will speed up research as it makes its results more realistic by replacing animal components with human components (https://tht-biomaterials.com).
HeartBeat.bio is an early-stage drug discovery company focused on the development of a high-throughput fully human 3D screening platform for heart diseases. The technology has the potential to radically change the current cardiovascular drug discovery paradigm, leading to higher success rates in clinical trials, reduced cost and time for compound development. HeartBeat.bio’s business strategy is to leverage its screening technology into multiple R
Sinsoma GmbH has the vision to make a significant contribution to a healthy and sustainable world by providing innovative molecular screening and test procedures. Sinsoma offers DNA
Since 1945, Montavit’s international business is focused on the production and distribution of pharmaceuticals and associated health related products. We are interested in sustainable and successful development of our business to safeguard our independence as a family owned company. For this reason, sustainability is a core feature of our business strategy. We have strong own brands which stimulate customer loyalty for our products and a number of reputable contract manufacturing partners.
Marinomed is a biopharmaceutical company specialized on innovative products based on the patent protected technology platforms Marinosolv® and the Carragelose®. The Marinosolv® technology platform enhances the efficacy of hardly soluble compounds with the lead product Budesolv having successfully completed a pivotal Phase III study. The Carragelose® platform is already used in six different products to treat viral infections of the respiratory tract including SARS-CoV-2.
OncoLab Diagnostics GmbH develops, manufactures, and distributes products for in vitro diagnostic applications and research.
SAICO is a Vienna-based company founded in 2017 that focuses on the microfabrication of biosensors and lab-on-a-chip systems for biomedical applications. We facilitate the rapid translation of academic innovations into industrial production of diagnostic tools for personalized medicine. Our core competence is the rapid and cost-efficient generation of functional prototypes needed to reduce the development time from initial idea to market-ready devices.
Arthro Kinetics Biotechnology GmbH: We develop, manufacture and distribute medical implants based on a proprietary and unique 3D Biomatrix from collagen type 1, which functions as a neutral organ scaffold for different types of cells. Today, our unique Matrix provides a proven three-dimensional cultivation environment for products and procedures to repair, to regenerate and to restore natural tissue function. With its applications, it proofs an extraordinary pathway since 2004.
We are a small private spin-off company from the Medical University of Graz, Austria. NGFI provides innovative products, services, support, and training for life science/medical researchers and biotech companies. We offer microscopic devices for research and special tools such as novel genetically encoded fluorescent probes as well as stable cell lines and research reagents in an affordable manner. Our main aim is to support scientists by providing products "from researchers for researchers".
Ablevia develops a new class of infusible therapeutics to selectively remove harmful and disease-causing antibodies. These therapeutics can be readily adapted to target unwanted antibodies in rare diseases or in conditions with unmet clinical needs. Founded in 2018 at the Vienna Biocenter Campus, Ablevia focuses on IP generation and preclinical research and development.